Author Summary {#s1}
==============

Discussion {#s2}
----------

QTcF correction change from baseline was the primary endpoint for this study. Fifty-one patients received at least 9 weeks of ramucirumab (10 mg/kg) plus diphenhydramine treatment (the complete corrected QT \[QTc\] evaluation period). Using the time-matched QTcF values from day −1 as the baseline, repeated-measures analysis of covariance showed that the upper limit of the two-sided 90% confidence intervals of the least square means of change from baseline for QTcF values was less than 10 milliseconds at all study time points in cycle 3 ([Fig. 1](#F1){ref-type="fig"}). The first 16 patients received treatment with moxifloxacin (400 mg orally), an antibiotic associated with mild QTc prolongation, which demonstrated assay sensitivity.

![Graph showing 90% confidence interval of change from baseline at cycle 3 for QTcF after ramucirumab plus diphenhydramine treatment. Red dotted line and blue dotted line indicate 10- and 5-millisecond time points, respectively. The scale of the *x*-axis (time) is non-uniform.\
Abbreviation: QTcF, QT corrected by Fridericia's formula.](theoncologist_15467CTR_f1){#F1}

The relationship between ramucirumab concentrations and change in QTcF was assessed using data from time points at which both the electrocardiogram data and the concentration data were available; the time-matched mean change from baseline QTcF was analyzed for correlation with the serum concentration of ramucirumab, using linear mixed models ([Fig. 2](#F2){ref-type="fig"}). The slope of the model in this analysis was not statistically significantly different from zero. The estimated value of the slope was −0.00207, showing a small negative association between concentration of ramucirumab and the change from baseline in QTcF. Mean ramucirumab concentration-time profiles at cycles 1 and 3 were very similar, with slightly higher mean concentrations for cycle 3, reflecting a small amount of accumulation following 3 doses of ramucirumab.

![QTcF changes from baseline versus total drug concentrations at cycle 3 for the evaluable population. Mean C~max~ = 571 µg/mL. Mean change in QTcF at mean C~max~ = 2.8 milliseconds (90% CI: −3.8 to 9.5).\
Abbreviations: CI, confidence interval; QTcF, QT corrected by Fridericia's formula.](theoncologist_15467CTR_f2){#F2}

Safety analyses included all treated patients (*n* = 66). Most treatment-emergent adverse events (TEAEs) in patients receiving ramucirumab were consistent with the known adverse event (AE) profile. Sixty-five patients experienced at least one TEAE, regardless of causality. Forty-two patients (63.6%) experienced at least one TEAE considered related to ramucirumab; the most common were headache (16.7%; 1.5% grade 3), nausea (15.2%), hypertension (10.6%; 4.5% grade 3), and vomiting (10.6%).

This phase II study demonstrated that ramucirumab did not produce a prolongation of QTcF. The 90% two-sided (95% one-sided) upper confidence limit did not exceed 10 milliseconds. This conclusion is also supported by concentration-QTcF modeling, which showed a visible but not significant negative association between concentration of ramucirumab and change from baseline in QTcF.
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